Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 20, Issue 8, 2013, Pages 566-574

  Chen, F ^a   He, J L ^b   Zheng, M ^a   Zhu, H H ^a   Li, S P ^a   Wang, K ^c   Zhang, X X ^d   Zhao, Y R ^e   Wu, S S ^a   Chen, Z ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

hepatitis B virus infection; inducible nitric oxide synthase; macrophage inflammatory protein 2; neutrophil gelatinase associated lipocalin; T cell immunoglobulin domain and mucin domain containing molecule 3

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING PROTEIN 3; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL;

HEPATITIS B VIRUS INFECTION; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN-DOMAIN-CONTAINING MOLECULE-3;

ADULT; ALANINE TRANSAMINASE; BILIRUBIN; BIOLOGICAL MARKERS; CYTOKINES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HEPATITIS B; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84879796539     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12067     Document Type: Article

References (31)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV,. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (10 Suppl 3): S158-S168.
2. World Health Organization. Hepatitis B. (Fact sheet no. 204). Geneva, Switzerland: World Health Organization, 2000. (http://www.who.int/mediacentre/ factsheets/fs204/en/index.html).
3. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2004; 79 (28): 255-263.
4. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
5. Sato S, Suzuki K, Akahane Y, et al,. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122 (4): 241-248.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45 (4): 529-538.
7. Bosch FX, Ribes J, Cléries R, Díaz M,. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9 (2): 191-211, v.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19 (6): 1513-1520.
9. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373 (9663): 582-592.
10. Chen F, Hai-Hong Z, Lin-Fu Z, et al,. Genes related to the very early stage of ConA-induced fulminant hepatitis: a gene-chip-based study in a mouse model. BMC Genomics 2010; 11: 240.
11. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, C.M.A. The guideline of prevention and treatment for chronic hepatitis B. (2010 version). Chin Prev Med 2011; 12 (1): 1-15.
12. Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Zhonghua Gan zangbing Zazhi 2000; 8 (6): 324-329.
13. Pratt DS, Kaplan MM,. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342 (17): 1266-1271.
14. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB,. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46 (12): 2027-2049.
15. Green RM, Flamm S,. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123 (4): 1367-1384.
16. Kim HJ, Oh SW, Kim DJ, Choi EY,. Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. Clin Chem 2009; 55 (5): 1022-1025.
17. Prati D, Taioli E, Zanella A, et al,. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137 (1): 1-10.
18. Sheth SG, Flamm SL, Gordon FD, Chopra S,. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93 (1): 44-48.
19. Brodkin CA, Daniell W, Checkoway H, et al,. Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 1995; 52 (10): 679-685.
20. Kelleher TB, Afdhal N,. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006; 44 (1 Suppl): S126-S131.
21. Bautista AP,. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the liver. Hepatology 1997; 25 (2): 335-342.
22. Driscoll KE,. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp Lung Res 1994; 20 (6): 473-490.
23. Njoku DB, Li Z, Mellerson JL, et al,. IP-10 protects while MIP-2 promotes experimental anesthetic hapten-induced hepatitis. J Autoimmun 2009; 32 (1): 52-59.
24. Sabatos CA, Chakravarti S, Cha E, et al,. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4 (11): 1102-1110.
25. Wu W, Shi Y, Li J, Chen F, Chen Z, Zheng M,. Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol J 2011; 8: 113.
26. Ju Y, Hou N, Meng J, et al,. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 2010; 52 (3): 322-329.
27. Lee MJ, Woo MY, Heo YM, et al,. The inhibition of the T-cell immunoglobulin and mucin domain 3 (Tim3) pathway enhances the efficacy of tumor vaccine. Biochem Biophys Res Commun 2010; 402 (1): 88-93.
28. Portal AJ, McPhail MJ, Bruce M,. et al. Neutrophil gelatinase-associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl 2010; 16 (11): 1257-1266.
29. Devarajan P,. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med 2010; 4 (2): 265-280.
30. Shin HJ, Park YH, Kim SU, et al,. Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase. J Biol Chem 2011; 286 (34): 29872-29881.
31. Bui-Nguyen TM, Pakala SB, Sirigiri DR, Martin E, Murad F, Kumar R,. Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem 2009; 285 (10): 6980-6986.